acl6kprq32009results991.htm






 
 
Exhibit 99.1
                                                 


 
For immediate release
 
Alcon Posts 5.9 Percent Sales Growth for Third Quarter
Third Quarter Highlights




·  

Organic sales growth was 9.0 percent
 




·   

Operating profit rose 17.0 percent to $578 million
 




·   

Sales of advanced technology intraocular lenses increased 34.2 percent
 




· 

Management raises outlook for full year earnings per share
 


HUENENBERG, Switzerland – October 27, 2009 – Alcon, Inc. (NYSE:ACL) reported global sales rose 5.9 percent to $1,614 million for the third quarter of 2009, or a 9.0 percent increase excluding the impact of foreign exchange fluctuations. Net earnings for
the third quarter of 2009 were $515 million, or $1.71 per diluted share. Excluding the impact of a $240 million tax benefit related to the refractive product line in 2008 and the impact of continuing expenses related to the first quarter 2009 reduction in force, adjusted net earnings for the third quarter 2009 would have grown 33.3 percent compared to non-GAAP adjusted net earnings for the third quarter of 2008.
“Continued execution of our operational strategies combined with an improved market environment drove our solid third quarter performance,” said Kevin Buehler, Alcon’s president and chief executive officer. “We continue to achieve organic sales growth and market share growth with contributions
from multiple areas, but especially from advanced technology intraocular lenses, glaucoma treatments and emerging markets. We expect these factors to continue to support solid organic growth, which, along with a more favorable currency environment, allows us to raise our earnings outlook for the remainder of the year.”


Sales Highlights
Summarized below are sales highlights for the third quarter of 2009. All growth comparisons are for the third quarter of 2009 compared to the third quarter of 2008. Organic sales growth rates exclude currency impacts and acquisitions and are non-GAAP measures that are reconciled in a table at the end of this release.
 




Ø  

International organic sales growth was 10.1 percent (+4.5 percent reported), with the Brazil, Russia, India and China (BRIC) nations leading organic growth, rising 13.3 percent (+0.6 percent reported).
 




Ø  

U.S. sales rose 7.6 percent as prescription demand improved and on strong revenue growth in glaucoma and advanced technology AcrySof® intraocular lenses.
 




Ø  

Global sales of advanced technology intraocular lenses rose 37.7 percent organically (34.2 percent reported) due to U.S. market share gains of the AcrySof® IQ
ReSTOR® +3.0 lens and broader and more frequent use of the AcrySof® IQ Toric lens by cataract surgeons.
 




Ø  

Global glaucoma sales increased 18.2 percent, led by a 23.6 percent rise in global sales of the TRAVATAN® family of products (TRAVATAN®, TRAVATAN
Z® and DuoTravTM ophthalmic solutions).  Azopt® and Azarga® ophthalmic
solutions also added to glaucoma sales growth, together rising 16.9 percent.
 




Ø  

The launch of the Constellation® vitreoretinal system contributed to a 19.5 percent growth of sales in the company’s vitreoretinal
business.
 
Earnings Highlights
 
Summarized below are earnings highlights for the third quarter of 2009. All growth comparisons are for the third quarter of 2009 compared to the third quarter of 2008.
 




Ø  

Gross profit margin was in line with management expectations at 75.3 percent compared to 77.2 percent in 2008. The decline was primarily attributable to the impact of foreign exchange rates on costs of goods sold in each period.
 




Ø  

Operating profit rose 17.0 percent and operating profit margin increased from 32.4 percent to 35.8 percent of sales. This improvement resulted from cost management programs that reduced selling, general and administrative expenses to 29.4 percent from 32.9 percent of sales. Research and development expenses were 9.8 percent of sales and were lower than
2008 due to timing differences for research projects and licensing transactions between the two periods.
 




Ø  

Net earnings in the third quarter of 2009 were $515 million compared to $627 million in 2008. Excluding a $240 million tax benefit in 2008 and the impact of continuing expenses related to the first quarter 2009 reduction in force, adjusted net earnings grew 33.3 percent.  This increase was attributable to reduced operating expenses and investment
portfolio gains compared to investment losses in the third quarter 2008.


Other Highlights
 




Ø  

On September 15, 2009, Alcon acquired the Swiss biotechnology firm ESBATech AG providing the company with a sustainable platform of biologic development utilizing antibody fragment technology particularly suited to treat ocular diseases.
 




Ø  

Alcon entered into a licensing and purchase option agreement in October with Potentia Pharmaceuticals for POT-4 for the treatment of age-related macular degeneration.
 




Ø  

On October 2, 2009, the company launched brimonidine 0.15% in the United States which is the only non-branded version of Alphagan® P 0.15% on the market.
 




Ø  

Alcon received approval for DisCoVisc® viscoelastic system, the PUREPOINT™ laser and the Laureate® world
phaco system in Japan in the third quarter of 2009.
 




Ø  

During the quarter Alcon received additional country approvals of Vigamox® ophthalmic solution and the drug is now approved in a majority of European Union countries.
 




Ø  

The U.S. District Court for the District of Delaware issued an opinion on October 19, 2009 finding in Alcon’s favor on all claims and defenses in the Vigamox case against Teva that was tried in March 2008.
 
Financial Guidance
The company reaffirmed its previously-issued sales guidance for full year 2009 organic sales growth to be in the mid-single digits. The company raised its guidance for full year 2009 diluted earnings per share on a U.S. GAAP basis to between $6.55 and $6.65 and between $6.60 and $6.70 on a non-GAAP adjusted basis
(excluding restructuring charges taken in 2009). This increase reflects the positive results year to date and an improving market environment, partially mitigated by the expectation of higher R&D and SG&A expenses in the remainder of the year.


Company Description
Alcon, Inc. is the world’s leading eye care company, with sales of $6.3 billion in 2008. Alcon, which has been dedicated to the ophthalmic industry for 65 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products
that treat diseases, disorders and other conditions of the eye. Alcon’s majority shareholder is Nestlé, S.A., the world’s largest food company. All trademarks noted in this release are the property of Alcon, Inc. For more information about Alcon, visit www.alcon.com.

 



  

  
  

  

 ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Earnings (Unaudited)
(in millions, except share data)





  
 

Three months ended
 
 

Nine months ended
 
  
 

September 30,
 
 

September 30,
 
  
 

2009
 
 

2008
 
 

2009
 
 

2008
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Sales
 
$
1,614
 
 
$
1,524
 
 
$
4,784
 
 
$
4,796
 

Cost of goods sold
 
 
399
 
 
 
348
 
 
 
1,168
 
 
 
1,161
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gross profit
 
 
1,215
 
 
 
1,176
 
 
 
3,616
 
 
 
3,635
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Selling, general and administrative
 
 
474
 
 
 
501
 
 
 
1,414
 
 
 
1,512
 

Research and development
 
 
158
 
 
 
174
 
 
 
461
 
 
 
461
 

Amortization of intangibles
 
 
5
 
 
 
7
 
 
 
17
 
 
 
22
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Operating income
 
 
578
 
 
 
494
 
 
 
1,724
 
 
 
1,640
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Other income (expense):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gain (loss) from foreign currency, net
 
 
--
 
 
 
(10 
)
 
 
(1 
)
 
 
(7 
)

Interest income
 
 
13
 
 
 
20
 
 
 
37
 
 
 
66
 

Interest expense
 
 
(3 
)
 
 
(13 
)
 
 
(13 
)
 
 
(45 
)

Other, net
 
 
6
 
 
 
(42 
)
 
 
12
 
 
 
(52 
)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Earnings before income taxes
 
 
594
 
 
 
449
 
 
 
1,759
 
 
 
1,602
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Income taxes
 
 
79
 
 
 
(178 
)
 
 
210
 
 
 
(21 
)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Net earnings
 
$
515
 
 
$
627
 
 
$
1,549
 
 
$
1,623
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic earnings per common share
 
$
1.72
 
 
$
2.10
 
 
$
5.19
 
 
$
5.44
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diluted earnings per common share
 
$
1.71
 
 
$
2.07
 
 
$
5.15
 
 
$
5.38
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Basic weighted average common shares
 
 
298,875,564
 
 
 
299,076,483
 
 
 
298,734,923
 
 
 
298,428,116
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diluted weighted average common shares
 
 
301,894,468
 
 
 
302,636,080
 
 
 
300,856,409
 
 
 
301,920,346
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Global Sales
(USD in millions)





  

Three Months Ended
  
  
  
  
  

Foreign
  
  
  
  
  
  

September 30,
  
  
  
  
  

Currency
  
  

Organic
  
  
  

2009
  

2008
  
  

Change
  
  

Change
  
  

Change
  
  

Geographic Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon United States:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical

$

324
  

$

301
  
  

7.6
  

%

--
  

%

7.6
  

%

Surgical
  

304
  
  

275
  
  

10.5
  
  

--
  
  

10.5
  
  

Consumer Eye Care
  

105
  
  

105
  
  

--
  
  

--
  
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total United States Sales
  

733
  
  

681
  
  

7.6
  
  

--
  
  

7.6
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon International:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical
  

335
  
  

308
  
  

8.8
  
  

(7.4

)
  

16.2
  
  

Surgical
  

435
  
  

417
  
  

4.3
  
  

(4.1

)
  

8.4
  
  

Consumer Eye Care
  

111
  
  

118
  
  

(5.9

)
  

(5.9

)
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total International Sales
  

881
  
  

843
  
  

4.5
  
  

(5.6

)
  

10.1
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

1,614
  

$

1,524
  
  

5.9
  
  

(3.1

)
  

9.0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Global Product Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Infection/inflammation

$

199
  

$

208
  
  

(4.3

)

%

(3.8

)

%

(0.5

)

%

Glaucoma
  

286
  
  

242
  
  

18.2
  
  

(3.7

)
  

21.9
  
  

Allergy
  

97
  
  

85
  
  

14.1
  
  

(1.2

)
  

15.3
  
  

Otic/nasal
  

106
  
  

86
  
  

23.3
  
  

(1.1

)
  

24.4
  
  

Other pharmaceuticals/rebates
  

(29

)
  

(12

)
  

N/M
  
  

N/M
  
  

N/M
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Pharmaceutical
  

659
  
  

609
  
  

8.2
  
  

(3.8

)
  

12.0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Intraocular lenses
  

278
  
  

256
  
  

8.6
  
  

(2.7

)
  

11.3
  
  

Cataract/vitreoretinal
  

436
  
  

408
  
  

6.9
  
  

(2.2

)
  

9.1
  
  

Refractive
  

25
  
  

28
  
  

(10.7

)
  

(3.6

)
  

(7.1

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Surgical
  

739
  
  

692
  
  

6.8
  
  

(2.4

)
  

9.2
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Contact lens disinfectants
  

119
  
  

119
  
  

--
  
  

(1.7

)
  

1.7
  
  

Artificial tears
  

73
  
  

73
  
  

--
  
  

(5.5

)
  

5.5
  
  

Other
  

24
  
  

31
  
  

(22.6

)
  

(3.2

)
  

(19.4

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Consumer Eye Care
  

216
  
  

223
  
  

(3.1

)
  

(3.1

)
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

1,614
  

$

1,524
  
  

5.9
  
  

(3.1

)
  

9.0
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N/M - Not Meaningful
Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit
volumes and local currency prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.  Certain reclassifications have been made to prior year amounts to conform to current year presentation.



  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Global Sales
(USD in millions)





  

Nine Months Ended
  
  
  
  
  

Foreign
  
  
  
  
  
  

September 30,
  
  
  
  
  

Currency
  
  

Organic
  
  
  

2009
  

2008
  
  

Change
  
  

Change
  
  

Change
  
  

Geographic Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon United States:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical

$

1,022
  

$

1,027
  
  

(0.5

)

%

--
  

%

(0.5

)

%

Surgical
  

858
  
  

805
  
  

6.6
  
  

--
  
  

6.6
  
  

Consumer Eye Care
  

301
  
  

309
  
  

(2.6

)
  

--
  
  

(2.6

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total United States Sales
  

2,181
  
  

2,141
  
  

1.9
  
  

--
  
  

1.9
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Alcon International:
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Pharmaceutical
  

976
  
  

956
  
  

2.1
  
  

(11.3

)
  

13.4
  
  

Surgical
  

1,311
  
  

1,353
  
  

(3.1

)
  

(10.0

)
  

6.9
  
  

Consumer Eye Care
  

316
  
  

346
  
  

(8.7

)
  

(11.0

)
  

2.3
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total International Sales
  

2,603
  
  

2,655
  
  

(2.0

)
  

(10.7

)
  

8.7
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

4,784
  

$

4,796
  
  

(0.3

)
  

(5.9

)
  

5.6
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Global Product Sales
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Infection/inflammation

$

609
  

$

667
  
  

(8.7

)

%

(5.4

)

%

(3.3

)

%

Glaucoma
  

793
  
  

705
  
  

12.5
  
  

(6.9

)
  

19.4
  
  

Allergy
  

400
  
  

384
  
  

4.2
  
  

(1.5

)
  

5.7
  
  

Otic/nasal
  

285
  
  

256
  
  

11.3
  
  

(2.0

)
  

13.3
  
  

Other pharmaceuticals/rebates
  

(89

)
  

(29

)
  

N/M
  
  

N/M
  
  

N/M
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Pharmaceutical
  

1,998
  
  

1,983
  
  

0.8
  
  

(5.4

)
  

6.2
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Intraocular lenses
  

815
  
  

805
  
  

1.2
  
  

(6.9

)
  

8.1
  
  

Cataract/vitreoretinal
  

1,276
  
  

1,263
  
  

1.0
  
  

(6.0

)
  

7.0
  
  

Refractive
  

78
  
  

90
  
  

(13.3

)
  

(5.5

)
  

(7.8

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Surgical
  

2,169
  
  

2,158
  
  

0.5
  
  

(6.3

)
  

6.8
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Contact lens disinfectants
  

341
  
  

356
  
  

(4.2

)
  

(3.4

)
  

(0.8

)
  

Artificial tears
  

208
  
  

209
  
  

(0.5

)
  

(9.6

)
  

9.1
  
  

Other
  

68
  
  

90
  
  

(24.4

)
  

(6.6

)
  

(17.8

)
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Consumer Eye Care
  

617
  
  

655
  
  

(5.8

)
  

(5.8

)
  

--
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Total Global Sales

$

4,784
  

$

4,796
  
  

(0.3

)
  

(5.9

)
  

5.6
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
N/M - Not Meaningful
Note: Organic change calculates sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit
volumes and local currency prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.  Certain reclassifications have been made to prior year amounts to conform to current year presentation.







  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(in millions, except share data)





  
 

September 30,
 
 

December 31,
 
  
 

2009
 
 

2008
 

Assets
 
 
 
 
 
 

Current assets:
 
 
 
 
 
 

Cash and cash equivalents
 
$
2,519
 
 
$
2,449
 

Short term investments
 
 
378
 
 
 
564
 

Trade receivables, net
 
 
1,332
 
 
 
1,168
 

Inventories
 
 
656
 
 
 
574
 

Deferred income tax assets
 
 
159
 
 
 
221
 

Other current assets
 
 
230
 
 
 
243
 
  
 
 
 
 
 
 
 
 

Total current assets
 
 
5,274
 
 
 
5,219
 
  
 
 
 
 
 
 
 
 

Long term investments
 
 
150
 
 
 
24
 

Property, plant and equipment, net
 
 
1,246
 
 
 
1,138
 

Intangible assets, net
 
 
259
 
 
 
91
 

Goodwill
 
 
690
 
 
 
645
 

Long term deferred income tax assets
 
 
398
 
 
 
342
 

Other assets
 
 
138
 
 
 
92
 
  
 
 
 
 
 
 
 
 

Total assets
 
$
8,155
 
 
$
7,551
 
  
 
 
 
 
 
 
 
 

Liabilities and Shareholders' Equity
 
 
 
 
 
 
 
 

Current liabilities:
 
 
 
 
 
 
 
 

Accounts payable
 
$
284
 
 
$
199
 

Short term borrowings
 
 
664
 
 
 
1,059
 

Current maturities of long term debt
 
 
1
 
 
 
1
 

Other current liabilities
 
 
1,003
 
 
 
931
 
  
 
 
 
 
 
 
 
 

Total current liabilities
 
 
1,952
 
 
 
2,190
 
  
 
 
 
 
 
 
 
 

Long term debt, net of current maturities
 
 
60
 
 
 
61
 

Long term deferred income tax liabilities
 
 
62
 
 
 
22
 

Other long term liabilities
 
 
681
 
 
 
587
 

Contingencies
 
 
 
 
 
 
 
 

Shareholders' equity:
 
 
 
 
 
 
 
 

Common shares, par value CHF 0.20 per share
 
 
42
 
 
 
42
 

Additional paid-in capital
 
 
1,508
 
 
 
1,449
 

Accumulated other comprehensive income
 
 
213
 
 
 
80
 

Retained earnings
 
 
4,076
 
 
 
3,699
 

Treasury shares, at cost
 
 
(439 
)
 
 
(579 
)
  
 
 
 
 
 
 
 
 

Total shareholders' equity
 
 
5,400
 
 
 
4,691
 
  
 
 
 
 
 
 
 
 

Total liabilities and shareholders' equity
 
$
8,155
 
 
$
7,551
 
  
 
 
 
 
 
 
 
 





  

  
  

  

ALCON, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in millions)



  
 

Nine months ended September 30,
 
  
 

2009
 
 

2008
 
  
 
 
 
 
 
 

Cash provided by (used in) operating activities:
 
 
 
 
 
 

Net earnings
 
$
1,549
 
 
$
1,623
 

Adjustments to reconcile net earnings to cash provided from
 
 
 
 
 
 
 
 

operating activities:
 
 
 
 
 
 
 
 

Depreciation
 
 
142
 
 
 
128
 

Amortization of intangibles
 
 
17
 
 
 
22
 

Share-based payments
 
 
58
 
 
 
70
 

Tax benefits (reversals) from share-based compensation
 
 
2
 
 
 
8
 

Deferred income taxes
 
 
41
 
 
 
(118 
)

Loss (gain) on sale of assets
 
 
61
 
 
 
9
 

Unrealized depreciation (appreciation) on trading securities
 
 
(73 
)
 
 
41
 

Other, net
 
 
(3 
)
 
 
7
 

Changes in operating assets and liabilities:
 
 
 
 
 
 
 
 

Trade receivables
 
 
(123 
)
 
 
(15 
)

Inventories
 
 
(34 
)
 
 
13
 

Other assets
 
 
(22 
)
 
 
24
 

Accounts payable
 
 
79
 
 
 
20
 

Other current liabilities
 
 
59
 
 
 
41
 

Other long term liabilities
 
 
22
 
 
 
(178 
)

Net cash from operating activities
 
 
1,775
 
 
 
1,695
 
  
 
 
 
 
 
 
 
 

Cash provided by (used in) investing activities:
 
 
 
 
 
 
 
 

Purchases of property, plant and equipment
 
 
(226 
)
 
 
(215 
)

Acquisition of business, net of cash acquired
 
 
(149 
)
 
 
--
 

Purchases of intangible assets
 
 
(4 
)
 
 
(28 
)

Purchases of investments
 
 
(795 
)
 
 
(816 
)

Proceeds from sales and maturities of investments
 
 
917
 
 
 
831
 

Other, net
 
 
7
 
 
 
4
 

Net cash from investing activities
 
 
(250 
)
 
 
(224 
)
  
 
 
 
 
 
 
 
 

Cash provided by (used in) financing activities:
 
 
 
 
 
 
 
 

Net proceeds from (repayment of) short term debt
 
 
(436 
)
 
 
(498 
)

Repayment of long term debt
 
 
(1 
)
 
 
(2 
)

Dividends on common shares
 
 
(1,048 
)
 
 
(750 
)

Acquisition of treasury shares
 
 
(5 
)
 
 
(44 
)

Proceeds from exercise of stock options
 
 
21
 
 
 
120
 

Tax benefits from share-based payment arrangements
 
 
2
 
 
 
51
 

Net cash from financing activities
 
 
(1,467 
)
 
 
(1,123 
)
  
 
 
 
 
 
 
 
 

Effect of exchange rates on cash and cash equivalents
 
 
12
 
 
 
9
 
  
 
 
 
 
 
 
 
 

Net increase (decrease) in cash and cash equivalents
 
 
70
 
 
 
357
 

Cash and cash equivalents, beginning of period
 
 
2,449
 
 
 
2,134
 
  
 
 
 
 
 
 
 
 

Cash and cash equivalents, end of period
 
$
2,519
 
 
$
2,491
 
  
 
 
 
 
 
 
 
 





  

  
  

  

 ALCON, INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Financial Measures





  
 

Net earnings
 
  
 
 
Q3 2009
 
 
 
Q3 2008
 
 

Growth
 
  
 
 
 
 
 
 
 
 
 
 
 

As Reported
 
$
515
 
 
$
627
 
 
 
(17.9
) %

2008 Tax Benefit
 
 
--
 
 
 
(240
)
 
 
 
 

2009 restructuring adjustment
 
 
1
 
 
 
--
 
 
 
 
 

As Adjusted
 
$
516
 
 
$
387
 
 
 
33.3 
%
  
 
 
 
 
 
 
 
 
 
 
 
 


Note: Adjusted net earnings measures the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company’s operations because it provides investors with a clearer picture of the core operations of the
company.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.





  
 

Reported Change
 
 

Foreign
Currency
Change
 
 

Organic
Change
 
  
 
 
 
 
 
 
 
 
 

BRIC nation sales
 
 
0.6
%
 
 
( 12.7
) %
 
 
13.3
%
  
 
 
 
 
 
 
 
 
 
 
 
 

Global advanced technology intraocular lens sales
 
 
34.2
%
 
 
( 3.5
) %
 
 
37.7
%


Note: Organic change presents sales growth without the impact of foreign exchange fluctuations and acquisitions. Management believes organic sales change is an important measure of the company’s operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit
volumes and local currency prices.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.








2009 reported
  

$

6.55-6.65
  

2009 restructuring adjustment
  
  

0.05
  

2009 adjusted
  

$

6.60-6.70
  
  
  
  
  
  


Note: Adjusted net earnings and diluted EPS measure the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company’s operations because it provides investors with a clearer picture of the core operations
of the company.  This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.



  

  
  

  

# # #
 
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements principally relate to statements regarding the expectations of our management with respect to the future performance of various aspects
of our business. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. Words such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "hope," "intend," "estimate," "project," "predict," "potential" and similar expressions are intended to identify forward-looking
statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties and are not intended to give any assurance as to future results. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that might cause future results to differ include, but are not limited to, the following: the development of commercially viable products may
take longer and cost more than expected; changes in reimbursement procedures by third-party payers may affect our sales and profits; a weakening economy could affect demand for our products; competition may lead to worse than expected financial condition and results of operations; currency exchange rate fluctuations may negatively affect our financial condition and results of operations; pending or future litigation may negatively impact our financial condition and results of operations; litigation settlements
may adversely impact our financial condition; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self-insured, may adversely impact our financial condition; product recalls or withdrawals may negatively impact our financial condition or results of operations; government regulation or legislation may negatively impact our financial condition or results of operations; changes in tax laws or regulations in the jurisdictions in which we and our subsidiaries
are subject to taxation may adversely impact our financial performance; supply and manufacturing disruptions could negatively impact our financial condition or results of operations. You should read this press release with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the
Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


For more information, contact:


Doug MacHatton
Vice President,Treasury and
Investor and Public Relations
(817) 551-8974
doug.machatton@alconlabs.com


John Selzer
Director, Investor Relations
(817) 568-6166
john.selzer@alconlabs.com


Bob Peterson
Manager, Investor Relations
(817) 551-4687
robert.peterson@alconlabs.com
www.alcon.com